Enhanced Cytotoxicity of Liposomal Daunorubicin in HCT116 Colorectal Cancer Cells: Modulation of Oxidative Stress and ERK1/2 gene expression

Imagine your body is a bustling city, and sometimes, a few buildings in that city (your cells) start acting up, growing wild and refusing to stop. This is what happens in colorectal cancer. For a long time, doctors have tried to stop these rogue buildings using a powerful tool called Daunorubicin (DNR). Think of DNR as a heavy-duty demolition crew. It's great at smashing the bad cells, but it's also a bit clumsy; it often knocks over the good buildings nearby and causes a lot of noise and damage to the whole neighborhood (the patient's body). Plus, the bad cells sometimes learn to build shields to block the demolition crew.

Enter the scientists Fariba Moharami, Zahra Pourjam, and their team. They asked a simple question: What if we could put that demolition crew inside a tiny, invisible bubble? This bubble is called a liposome.

The Magic Bubble

The team built these bubbles in their lab. They are so small that 118.3 of them lined up would barely stretch across the width of a human hair. They are also very stable, with a "charge" of -50.7 mV that keeps them from sticking together, like magnets that repel each other.

They filled these bubbles with Daunorubicin to create Liposomal Daunorubicin (LDNR). Then, they took a specific type of cancer cell, HCT116 (a stubborn little rebel from the colon), and set up a showdown.

The Showdown: Free vs. Encapsulated

The scientists treated the cancer cells with two things:

1. Free DNR: The demolition crew walking around without a bubble.
2. LDNR: The demolition crew riding inside the magic bubble.

They watched what happened over 72 hours (three full days).

The Result? The bubble won, and it won big.
When they used the same amount of drug (0.5 µM), the free DNR killed about 60.4% of the cancer cells. But the liposomal version? It killed 70.8% of them. That's a significant difference!

Even more impressive, the team found that the liposomal version was much more powerful overall. They calculated the "IC50," which is the amount of drug needed to kill half the cells. The free drug needed 0.5 µM to do the job. The liposomal version only needed 0.18 µM. That means the bubble version is nearly three times more potent, doing more damage with less "ammo."

How Did the Bubble Win?

The scientists looked under the microscope to see how the cells died. The cells hit by the liposomal bubbles looked like they were in a panic. They shrank into perfect spheres, their nuclei (the command centers) got super dense and squished, and they looked ready to pop. This is the classic look of apoptosis, or programmed cell death. The free drug caused some of this, but the liposomal version made it happen much more dramatically.

But why? The paper suggests three main reasons, acting like a triple-threat attack:

1. The Stress Bomb (Oxidative Stress):
   Cancer cells usually try to keep their internal environment calm. The liposomal drug, however, acts like a stress bomb. It floods the cell with Reactive Oxygen Species (ROS)—think of these as tiny, angry sparks.

   • In the control group (no drug), only 1.7% of cells had these sparks.
   • The free drug raised this to 22.3%.
   • The liposomal drug? It skyrocketed to 38.6% (the abstract mentions 36.8%, but the results section clarifies 38.6%).
     The bubble delivered so many sparks that the cell's internal fire extinguishers couldn't handle it.

2. Disarming the Shields (Total Antioxidant Capacity):
   The cells tried to fight back by using their own antioxidants (their fire extinguishers). The scientists measured how strong these shields were.

   • Healthy cells had a shield strength of 0.42 U/mL.
   • The free drug dropped this to 0.09 U/mL.
   • The liposomal drug smashed the shield down even further to 0.03 U/mL.
     The bubble didn't just throw more sparks; it broke the cells' ability to put them out.

3. Shutting Down the "Stay Alive" Signal (ERK1/2):
   Cancer cells have a "stay alive" switch called the ERK1/2 gene. It tells the cell to keep growing.

   • The free drug turned this switch down to 0.28 of its normal level.
   • The liposomal drug turned it way down to 0.08.
     This means the bubble version was much better at silencing the "stay alive" signal, forcing the cell to give up.

What the Paper Does Not Say

It's important to know what this study didn't do. The authors are very clear: this was a lab experiment using cells in a dish. They did not test this on actual people or animals in this specific study. The HCT116 cell line they used is a commercially available resource, meaning no live animals were involved in the experiments described in this paper.

They also note that while they measured the "stay alive" gene (ERK1/2) and saw it drop, they didn't measure the active protein version of that gene in this specific experiment. They suggest that future studies should check the protein to be absolutely sure the signal is truly off, but based on the gene data, the signal is definitely dimmed.

The Bottom Line

The paper concludes that wrapping Daunorubicin in a liposomal bubble makes it a much sharper, more effective weapon against these specific cancer cells. It kills more cells, creates more internal stress, breaks the cells' defenses, and silences their survival signals better than the free drug.

The authors suggest this is a promising path for treating colorectal cancer, but they are careful to say that before it becomes a real treatment for patients, it needs to be tested in living organisms (in vivo) to see if it works the same way in a whole body. For now, in the world of these specific cells, the magic bubble is the clear winner.